Neshima Medical
Life-saving Treatments for Severe Respiratory Diseases
Company Overview
Snapshot
Founded in April 2020 by Yan Ostrovski, Ramy Fishler, Avital Frenkel, and Josué Sznitman, Neshima Medical operates with 1–10 employees. The company has secured funding across two rounds. In December 2025, Neshima Medical received a funding round led by embARC Ventures.
Business overview
Neshima Medical is a Health Tech & Life Sciences company developing life-saving treatments for severe lung diseases. Its core technology is LiFT™, a patented foam-based delivery platform designed to enable deep and uniform therapeutic delivery to the alveoli, overcoming the limitations of traditional treatments. The company's lead applications include a regenerative cell therapy for COPD and an ICU-delivered antibiotic treatment for antimicrobial-resistant infections. Neshima Medical targets the B2B market in Europe, Israel, and North America, operating within the Pharma & Medical Biotechnology and Drug Delivery sectors.
Strategic signal
In April 2020, Neshima Medical's pioneering foam therapy, developed at the Technion, garnered significant attention from multiple news outlets, including Haaretz and Jewish Business News. This widespread coverage highlighted the potential of their technology to improve the effectiveness of existing drugs in treating lung diseases and offered new hope for patients with acute respiratory distress syndrome, including those affected by the coronavirus. This early validation signals strong scientific interest and potential for broad impact in critical care and respiratory medicine.
Log in to access full profile ›Q&A
- What are Neshima Medical's main competitive advantages in the Health Tech & Life Sciences market? ›
- How has the company's funding evolved over time? ›
- Which customers or partners use Neshima Medical's technology? ›
- What is Neshima Medical's intellectual property portfolio? ›
- Who are the key competitors in the Health Tech & Life Sciences space? ›